Evolent Health, INC 10-Q quarterly reports

Evolent Health, Inc. announced its second quarter 2026 financial results, showing a substantial increase in revenue but also a significant rise in operating expenses and a wider net loss.

Evolent Health reported a 2.6% revenue increase in Q1 2026, driven by new contracts, but saw its net loss widen due to higher claims costs and increased interest expenses.

Evolent Health reported a 22.8% revenue decline in Q3 2025 due to contractual changes, but improved operating income, while undertaking significant debt refinancing and asset disposal.

Evolent Health, Inc. reported a significant revenue decrease and increased net loss for Q2 2025, driven by customer contract changes and higher medical claims costs, while actively restructuring its debt.

Evolent Health's Q1 2025 revenue decreased by 24.4% year-over-year, primarily due to contractual updates and industry-wide medical claims cost increases.

Evolent Health's Q3 2024 revenue increased by 21.6% year-over-year, but higher-than-expected medical costs in its specialty Performance Suite business impacted profitability.

Evolent Health's Q2 2024 results show a significant revenue increase driven by new risk contracts, while the company concludes its 2023 repositioning plan.

Evolent Health's first quarter of 2024 saw a significant revenue increase, but also a rise in costs, leading to a net loss.